Skip to content
product

Why the EDC Market Needs Disruption

The clinical data capture market is broken. Enterprise EDCs cost $500K-$2M per year, locking out 70% of research teams. Here's how AI and modern technology are the answer.

PT
PharmaTrialsCortex Team
|

The $2 Million Problem

If you run clinical trials, you already know the number. Enterprise Electronic Data Capture platforms — the software that records every data point in a regulated trial — cost between $500,000 and $2 million per year. That price tag includes licensing fees, per-study charges, per-site fees, user seat costs, and professional services for study builds that routinely take 10 to 12 weeks.

For the top 20 pharmaceutical companies, that cost is a rounding error. For everyone else — academic medical centers, small biotechs running Phase I-II trials, government-funded researchers, and CROs operating in emerging markets — it is a barrier that shapes what research gets done and what does not.

The result is a market where roughly 70% of clinical research teams are priced out of purpose-built EDC tools. They resort to spreadsheets, paper CRFs, or general-purpose survey tools that were never designed for regulatory compliance. The data suffers. The patients waiting for new treatments suffer.

What REDCap Proved

Consider REDCap. Developed at Vanderbilt University and released as a free tool for academic research, REDCap now supports over 1.3 million projects across 154 countries. It demonstrated conclusively that accessible tools transform the volume and quality of clinical research.

But REDCap was designed for research data capture broadly, not for the specific demands of regulated clinical trials. It lacks native 21 CFR Part 11 compliance, CDISC data standards, randomization engines, adverse event workflows, and the layered audit trail requirements that the FDA expects. Teams using REDCap for regulated work spend enormous effort building compliance workarounds on top of a foundation that was never designed for that purpose.

The clinical trial community needs what REDCap did for research data capture, applied specifically to regulated trials: a modern, AI-powered platform built from the ground up for compliance — at a fraction of enterprise pricing.

Why AI Changes Everything

The real cost driver in clinical trials is not software licensing — it is the manual labor the software demands. Study builds take 10-12 weeks because a human must read a 200-page protocol and manually configure every visit, form, and edit check. Medical coding takes hours because a human must map every adverse event term to MedDRA dictionaries. Data queries pile up because generic “please clarify” queries create weeks of back-and-forth.

AI eliminates these bottlenecks:

Automated study builds. Upload your protocol PDF. AI extracts visit schedules, CRF fields, edit checks, and eligibility criteria. Go live in days instead of months. Our target: 80% faster study configuration.

Intelligent coding. AI suggests MedDRA and WHO Drug Dictionary codes with confidence scores, learning from corrections. Target: 85%+ first-pass accuracy, reducing manual coding effort by 60%.

Smart queries. Instead of “please clarify,” AI generates context-aware queries that explain the issue and suggest resolution. Target: 30% faster query resolution with fewer response rounds.

Real-time anomaly detection. ML models flag outliers at the moment of entry, not weeks later during retrospective review. Target: 40% fewer preventable queries.

What We Are Building

PharmaTrialsCortex SmartEDC is an AI-enhanced EDC platform built specifically for regulated clinical trials. Every architectural decision starts from compliance requirements and works outward:

  • Immutable audit trails. Every change to clinical data creates an append-only record: who changed what, when, the old value, the new value, and why. The audit model has no update or delete permissions — not at the application layer, not at the database layer.

  • Electronic signatures. Full 21 CFR Part 11 Section 11.50 compliance: printed name, date and time, meaning of the signature, and re-authentication at the moment of signing.

  • Dynamic eCRF forms. Study forms are defined as JSON schemas and stored in the database. No code changes required to add a new CRF type. Build a study in the UI, not in a configuration file.

  • Role-based access control. Eight predefined clinical trial roles (Clinician, Data Manager, Auditor, Statistician, and more) with site-scoped data isolation. No user sees data they are not authorized to access.

  • PostgreSQL-native. JSONB for flexible form data, field-level PII encryption via pgcrypto, and UUID primary keys throughout.

The platform combines enterprise-grade compliance with AI-powered automation at accessible pricing — starting at $999/month with no per-user fees.

Who This Is For

We built PharmaTrialsCortex for the teams that the enterprise EDC market has left behind:

Academic research institutions running investigator-initiated trials on grant funding. You need Part 11 compliance without Part 11 pricing.

Small-to-mid biotechs running Phase I and Phase II studies. You need a real EDC, not a spreadsheet with an audit plugin bolted on.

CROs managing multi-site trials across countries. You need a platform with AI-powered automation that reduces your operational overhead.

Government-funded researchers accountable to public institutions. You need enterprise-quality tools at a price point that respects public funding.

The Road Ahead

We are currently in Phase 2 — full data management with edit checks, auto-queries, source data verification, database lock, consent management, and randomization. Phase 3 introduces AI capabilities: protocol-to-eCRF generation, auto-coding, anomaly detection, and smart query generation.

If the cost of your EDC is the bottleneck between a promising therapy and the patients who need it, something is fundamentally wrong with the market. We intend to fix it.

Interested in seeing PharmaTrialsCortex SmartEDC in action? Request a demo or contact us at hello@pharmatrialscortex.com.